Answers are grounded in this paper and cite their sources.
Activating mutations of the anaplastic lymphoma kinase (ALK) gene were identified in the pediatric tumor neuroblastoma, in 2008. Rapid translation of this finding into targeted neuroblastoma therapy was facilitated by the availability of ALK inhibitors developed for adult malignancies and an efficient preclinical and clinical research program. See related article by Foster et al., p. 3543
No takes yet. Share an insight, caveat, or question.
Schulte et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: